ARG (nordicARG™)
A fragment of aggrecan from IGD1-2 released by ADAMTS-4/5, enabling non-invasive assessment of cartilage degradation and turnover in joint diseases.
Key features and values
- Quantifies aggrecan fragments produced by aggrecanase-mediated cleavage.
- Reflects cartilage extracellular matrix degradation and turnover.
- Provides a non-invasive measure of cartilage breakdown in joint diseases.
- Supports monitoring of disease progression and therapeutic response.
- Applicable in research on osteoarthritis and other degenerative joint conditions.
- Facilitates evaluation of interventions targeting cartilage preservation.
- Complements other biomarkers for comprehensive joint health assessment.
Description
The ARG biomarker assay measures specific aggrecan fragments generated through aggrecanase activity, serving as an indicator of cartilage degradation and extracellular matrix turnover. This non-invasive assay provides insights into cartilage breakdown processes, supporting research and therapeutic development in joint diseases such as osteoarthritis. By quantifying aggrecan degradation products, the ARG assay aids in monitoring disease progression, evaluating treatment efficacy, and understanding the underlying mechanisms of cartilage pathology.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
